Alaunos Therapeutics, Inc.
TCRT
$3.69
$0.133.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 100.00% | 300.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 100.00% | 300.00% | -- |
| Cost of Revenue | 227.97% | 2.78% | 175.40% | -109.22% | -96.09% |
| Gross Profit | -227.97% | -5.11% | -176.00% | 109.66% | 96.09% |
| SG&A Expenses | -28.70% | -13.74% | -53.80% | -65.20% | -71.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.22% | -11.20% | -37.23% | -77.42% | -84.10% |
| Operating Income | -3.22% | 10.89% | 37.31% | 77.53% | 84.10% |
| Income Before Tax | -2.84% | 6.91% | 36.21% | 90.54% | 86.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.84% | 6.91% | 36.21% | 90.54% | 86.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.84% | 6.91% | 36.21% | 90.54% | 86.70% |
| EBIT | -3.22% | 10.89% | 37.31% | 77.53% | 84.10% |
| EBITDA | -3.17% | 10.86% | 37.27% | 75.81% | 82.46% |
| EPS Basic | 24.57% | 11.13% | 36.21% | 90.54% | 86.71% |
| Normalized Basic EPS | 24.57% | 11.14% | 36.21% | 77.20% | 84.01% |
| EPS Diluted | 24.57% | 11.13% | 36.21% | 90.54% | 86.71% |
| Normalized Diluted EPS | 24.57% | 11.14% | 36.21% | 77.20% | 84.01% |
| Average Basic Shares Outstanding | 36.33% | 4.75% | 0.00% | 0.00% | 0.06% |
| Average Diluted Shares Outstanding | 36.33% | 4.75% | 0.00% | 0.00% | 0.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |